LOINC Home

{component}   LP432695-7

Laboratory   LP29693-6

Molecular pathology   LP7822-2

Molecular Pathology Panels   LP62072-1

Noninvasive prenatal fetal aneuploidy and microdeletion panel   LP185919-0

Noninvasive prenatal fetal aneuploidy and microdeletion panel | Plasma cell-free+WBC DNA | Molecular Pathology Panels   LP401929-7

Noninvasive prenatal fetal aneuploidy and microdeletion panel based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific circulating cell free (ccf) DNA   75547-0

LOINC Code


LOINC code75547-0
nameNoninvasive prenatal fetal aneuploidy and microdeletion panel based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific circulating cell free (ccf) DNA
descriptionNoninvasive prenatal screening is used to assess fetal risk for various genetic conditions without requiring invasive maternal procedures such as amniocentesis or chorionic villus sampling. Cell-free DNA (cfDNA) in maternal plasma comes from both fetal and maternal sources, and depending on the technology used, this DNA can be used to determine fetal risk for a variety of conditions including aneuploidy (e.g., Trisomy 21, Monosomy X) and microdeletions (e.g., 22q11.2 deletion). This panel was developed for, but is not limited in use to, Natera's Panorama prenatal test, which incorporates SNP analysis of maternal white blood cell DNA with combined maternal and fetal cfDNA SNP analysis. Natera's proprietary informatics analysis method (NATUS) effectively subtracts the maternal genotype from the cfDNA genotype and analyzes the remaining fetal cfDNA genotype for certain aneuploidies and microdeletion syndromes.
statusACTIVE

Fully-Specified Name

componentNoninvasive prenatal fetal aneuploidy and microdeletion panel
property-
timePt  =  Point in time:  To identify measures at a point in time. This is a synonym for “spot” or “random” as applied to urine measurements.
systemWBC.DNA+Plas.cfDNA
scale-
methodDosage of chromosome specific cf DNA

Additional Names

short nameNIP aneu microdel pnl WBC.DNA+cfDNA

Basic Attributes

classPANEL.MOLPATH
type1  Laboratory
order vs. observationOrder

Panel Components

43993-5Age at delivery
18185-9Gestational age
75607-2Paternal sample received Qualitative
75605-6Cell-free DNA.fetal/Cell-free DNA.total in Plasma cell-free DNA by Dosage of chromosome-specific cfDNA
75606-4Cell-free DNA.fetal/Cell-free DNA.total in Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Narrative
75604-9Fetal sex in Cell-free+Maternal WBC DNA by Dosage of chromosome specific circulating cell free (ccf) DNA
75560-3Fetal Trisomy 21 prior risk [Likelihood] Based on maternal age
75562-9Fetal Trisomy 21 prior risk [Likelihood] Based on maternal age Narrative
75561-1Fetal Trisomy 21 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA
75563-7Fetal Trisomy 21 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75564-5Fetal Trisomy 21 risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative
75565-2Comment on fetal Trisomy 21 risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75554-6Fetal Trisomy 18 prior risk [Likelihood] Based on maternal age
75556-1Fetal Trisomy 18 prior risk [Likelihood] Based on maternal age Narrative
75555-3Fetal Trisomy 18 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA
75557-9Fetal Trisomy 18 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75558-7Fetal Trisomy 18 risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative
75559-5Comment on fetal Trisomy 18 risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75546-2Fetal Trisomy 13 prior risk [Likelihood] Based on maternal age
75550-4Fetal Trisomy 13 prior risk [Likelihood] Based on maternal age Narrative
75548-8Fetal Trisomy 13 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA
75551-2Fetal Trisomy 13 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75552-0Fetal Trisomy 13 risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative
75553-8Comment on fetal Trisomy 13 risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75566-0Fetal Monosomy X prior risk [Likelihood] Based on maternal age
75568-6Fetal Monosomy X prior risk [Likelihood] Based on maternal age Narrative
75567-8Fetal Monosomy X risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA
75569-4Fetal Monosomy X risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75570-2Fetal Monosomy X risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative
75571-0Comment on fetal Monosomy X risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75572-8Fetal Triploidy risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative
75573-6Comment on fetal Triploidy risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75574-4Fetal 22q11.2 deletion prior risk [Likelihood] based on general population risk
75575-1Fetal 22q11.2 deletion prior risk [Likelihood] based on general population risk Narrative
75576-9Fetal 22q11.2 deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA
75577-7Fetal 22q11.2 deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75578-5Fetal 22q11.2 deletion risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative
75579-3Comment on fetal 22q11.2 deletion risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75598-3Fetal 1p36 deletion prior risk [Likelihood] based on general population risk
75599-1Fetal 1p36 deletion prior risk [Likelihood] based on general population risk Narrative
75600-7Fetal 1p36 deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA
75601-5Fetal 1p36 deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75602-3Fetal 1p36 deletion risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative
75603-1Comment on fetal 1p36 deletion risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75586-8Fetal Angelman syndrome prior risk [Likelihood] based on general population risk
75587-6Fetal Angelman syndrome prior risk [Likelihood] based on general population risk Narrative
75588-4Fetal Angelman syndrome risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA
75589-2Fetal Angelman syndrome risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75590-0Fetal Angelman syndrome risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative
75591-8Comment on fetal Angelman syndrome risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75592-6Fetal 5p deletion prior risk [Likelihood] based on general population risk
75593-4Fetal 5p deletion prior risk [Likelihood] based on general population risk Narrative
75594-2Fetal 5p deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA
75595-9Fetal 5p deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75596-7Fetal 5p deletion risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative
75597-5Comment on fetal 5p deletion risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75580-1Fetal Prader-Willi syndrome prior risk [Likelihood] based on general population risk
75581-9Fetal Prader-Willi syndrome prior risk [Likelihood] based on general population risk Narrative
75582-7Fetal Prader-Willi syndrome risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA
75583-5Fetal Prader-Willi syndrome risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75584-3Fetal Prader-Willi syndrome risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative
75585-0Comment on fetal Prader-Willi syndrome risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative
75544-7Noninvasive prenatal testing overall interpretation Qualitative
75545-4Noninvasive prenatal testing comment [Text]
75608-0Citation [Bibliographic Citation] in Referral lab test Narrative
68989-3Performing laboratory [Address]
75549-6Performing laboratory phone number

Associated Observations

LOINC codes that represent optional associated observation(s) for a clinical observation or laboratory test. A LOINC term may represent a single associated observation or panel containing several associated observations.

History/Usage

first released
last updated2.73
last change typeMIN  - change to field other than name

Related Names

Chromosom
Chromosomes
Leukocytes
Molecular pathology
MOLPATH
NIP fet aneu microdel pnl
Pan
Panel.molpath
Panl
Pl
 Plasma
Plsm
Pnl
Point in time
Random
Spec
WBC.DNA+cfDNA
WBCs
White blood cells

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.